We report, for the first time to the best of our knowledge, the largest cohort of serial hs-TnI surveillance in patients diagnosed with cancer and treated with ICIs therapies,” the researchers wrote.

The annual growth in national health spending is expected to be higher than average gross domestic product growth in the US during 2024-2033.

The composition of the gut microbiome appears to be associated with treatment response in patients with pancreatic cancer, research suggests.

Cancer Therapy Advisor, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Zegfrovy (sunvozertinib) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC ...

Invikafusp alfa, a dual T-cell agonist targeting subsets of tumor-infiltrating lymphocytes, can elicit responses in patients with heavily pretreated gastrointestinal cancers, according to research ...

The FDA approved Lynozyfic (linvoseltamab-gcpt) to treat adults with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.

Adding atezolizumab and bevacizumab to TACE can improve outcomes in previously untreated, unresectable HCC, data suggest.

President Donald Trump’s “One Big Beautiful Bill” cuts federal spending on Medicaid and Affordable Care Act marketplaces by about $1 trillion over a decade, according to the nonpartisan Congressional ...

Provisions in the new tax and spending bill passed by the Senate would go even further than the House bill in removing health ...

Research presented at the ASCO Annual Meeting 2025 highlighted potential new standards of care and other advances in ...

Waiting about 9 months or more to rechallenge patients with amivantamab can improve outcomes in patients with colorectal cancer, data suggest.